BR112021026201A8 - Vírus de dengue atenuados - Google Patents
Vírus de dengue atenuadosInfo
- Publication number
- BR112021026201A8 BR112021026201A8 BR112021026201A BR112021026201A BR112021026201A8 BR 112021026201 A8 BR112021026201 A8 BR 112021026201A8 BR 112021026201 A BR112021026201 A BR 112021026201A BR 112021026201 A BR112021026201 A BR 112021026201A BR 112021026201 A8 BR112021026201 A8 BR 112021026201A8
- Authority
- BR
- Brazil
- Prior art keywords
- dengue virus
- modified
- virus
- recoded
- regions
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title abstract 2
- 230000002238 attenuated effect Effects 0.000 title abstract 2
- 241000710831 Flavivirus Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004705 Codon Proteins 0.000 abstract 1
- 108700010070 Codon Usage Proteins 0.000 abstract 1
- 241000710827 Dengue virus 1 Species 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866477P | 2019-06-25 | 2019-06-25 | |
| PCT/US2020/039166 WO2020263850A1 (en) | 2019-06-25 | 2020-06-23 | Attenuated dengue viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021026201A2 BR112021026201A2 (pt) | 2022-02-15 |
| BR112021026201A8 true BR112021026201A8 (pt) | 2022-05-10 |
Family
ID=74060347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026201A BR112021026201A8 (pt) | 2019-06-25 | 2020-06-23 | Vírus de dengue atenuados |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220347285A1 (https=) |
| EP (2) | EP3990014A4 (https=) |
| JP (2) | JP2022540773A (https=) |
| CN (1) | CN114302738A (https=) |
| AU (1) | AU2020307532A1 (https=) |
| BR (1) | BR112021026201A8 (https=) |
| CA (1) | CA3145401A1 (https=) |
| CL (1) | CL2021003475A1 (https=) |
| CO (1) | CO2021017772A2 (https=) |
| CR (1) | CR20210677A (https=) |
| DO (1) | DOP2021000271A (https=) |
| IL (1) | IL289274A (https=) |
| MX (1) | MX2022000038A (https=) |
| PE (1) | PE20220296A1 (https=) |
| PH (1) | PH12021553305A1 (https=) |
| WO (1) | WO2020263850A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12178869B2 (en) | 2017-12-22 | 2024-12-31 | Codagenix Inc. | Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer |
| WO2019172982A1 (en) | 2018-03-08 | 2019-09-12 | Codagenix Inc. | Attenuated flaviviruses |
| CN119899808A (zh) * | 2024-12-05 | 2025-04-29 | 深圳湾实验室 | 登革减毒株及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2587084C (en) * | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| KR101621100B1 (ko) | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| US20120269849A1 (en) | 2009-10-09 | 2012-10-25 | Eckard Wimmer | Attenuated influenza viruses and vaccines |
| JP2016523251A (ja) * | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
| BR112017004452B1 (pt) * | 2014-09-05 | 2023-12-12 | The Research Foundation For The State University Of New York | Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado |
| US11111481B2 (en) * | 2015-09-30 | 2021-09-07 | Ramot At Tel-Aviv University Ltd. | Attenuated virus mutated at sites of evolutionarily conserved RNA structure |
| CA3016697A1 (en) * | 2016-03-11 | 2017-09-14 | The Johns Hopkins University | Live attenuated zika virus vaccine |
| WO2019172982A1 (en) * | 2018-03-08 | 2019-09-12 | Codagenix Inc. | Attenuated flaviviruses |
-
2020
- 2020-06-23 CA CA3145401A patent/CA3145401A1/en active Pending
- 2020-06-23 CR CR20210677A patent/CR20210677A/es unknown
- 2020-06-23 AU AU2020307532A patent/AU2020307532A1/en active Pending
- 2020-06-23 US US17/621,125 patent/US20220347285A1/en active Pending
- 2020-06-23 MX MX2022000038A patent/MX2022000038A/es unknown
- 2020-06-23 BR BR112021026201A patent/BR112021026201A8/pt unknown
- 2020-06-23 EP EP20833206.4A patent/EP3990014A4/en active Pending
- 2020-06-23 PH PH1/2021/553305A patent/PH12021553305A1/en unknown
- 2020-06-23 CN CN202080060629.9A patent/CN114302738A/zh active Pending
- 2020-06-23 WO PCT/US2020/039166 patent/WO2020263850A1/en not_active Ceased
- 2020-06-23 JP JP2021576889A patent/JP2022540773A/ja active Pending
- 2020-06-23 PE PE2021002239A patent/PE20220296A1/es unknown
- 2020-06-23 EP EP26150104.3A patent/EP4707387A2/en active Pending
-
2021
- 2021-12-22 DO DO2021000271A patent/DOP2021000271A/es unknown
- 2021-12-22 IL IL289274A patent/IL289274A/en unknown
- 2021-12-24 CL CL2021003475A patent/CL2021003475A1/es unknown
- 2021-12-24 CO CONC2021/0017772A patent/CO2021017772A2/es unknown
-
2024
- 2024-12-24 JP JP2024227640A patent/JP2025041836A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553305A1 (en) | 2022-08-01 |
| CL2021003475A1 (es) | 2023-01-06 |
| IL289274A (en) | 2022-02-01 |
| CR20210677A (es) | 2022-04-26 |
| MX2022000038A (es) | 2022-02-24 |
| WO2020263850A1 (en) | 2020-12-30 |
| EP3990014A1 (en) | 2022-05-04 |
| CA3145401A1 (en) | 2020-12-30 |
| BR112021026201A2 (pt) | 2022-02-15 |
| CO2021017772A2 (es) | 2022-04-19 |
| CN114302738A (zh) | 2022-04-08 |
| JP2022540773A (ja) | 2022-09-20 |
| US20220347285A1 (en) | 2022-11-03 |
| DOP2021000271A (es) | 2022-04-18 |
| JP2025041836A (ja) | 2025-03-26 |
| AU2020307532A1 (en) | 2022-01-27 |
| PE20220296A1 (es) | 2022-03-07 |
| EP4707387A2 (en) | 2026-03-11 |
| EP3990014A4 (en) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551355A1 (en) | Attenuated flaviviruses | |
| BR112021026201A8 (pt) | Vírus de dengue atenuados | |
| CL2019000993A1 (es) | Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| BR112017014917A2 (pt) | elementos regulatórios pós-transcricionais modificados de hepatite | |
| MX2020013853A (es) | Compuestos innovadores. | |
| BR112015021341A2 (pt) | anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos | |
| CU20200037A7 (es) | Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) | |
| BR112022016580A2 (pt) | Composições e métodos para induzir uma resposta imune | |
| MY192806A (en) | Compositions and methods of vaccination against dengue virus in children and young adults | |
| CL2021002307A1 (es) | Uso de virus oncolíticos para el tratamiento del cáncer | |
| BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
| AR072302A1 (es) | Pestivirus atenuados. composicion inmunogenica. metodo. | |
| BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
| WO2022226423A3 (en) | Therapeutic interfering particles for corona virus | |
| BR112022010425A2 (pt) | Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b | |
| BR112022001912A2 (pt) | Composições celulares compreendendo vetores virais e métodos de tratamento | |
| MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
| BR112021024593A2 (pt) | Composição explosiva, método de preparação e uso da mesma | |
| EA201700340A1 (ru) | Биологически активное вещество полифармакологического действия растительного происхождения | |
| BR112014015582A2 (pt) | compostos antivirais | |
| BR112022019717A2 (pt) | Peptídeos antivirais de amplo espectro | |
| BR112022023135A2 (pt) | Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas | |
| BRPI0516542A (pt) | composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária |